Some Alzheimer's risk shows up on brain scans before symptoms because amyloid buildup followed by tau tangles starts more than a decade before clear memory loss. Tests spot that silent biology during what doctors call preclinical disease, meaning brain change without evident impairment, according to the Alzheimer's Association Workgroup summary Alzheimer's Association Workgroup summary. That shift matters for families. A scan or blood marker can signal higher future risk while thinking still seems normal, but it does not predict timing for any one person.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What are scans finding so early?
- Why do genes make the signal stronger?
- Can you get tested without symptoms?
- What does a positive result mean?
What are scans finding so early?
The earliest change is amyloid accumulation in the brain, followed by tau tangles. This sequence unfolds over many years before impairment meets clinical thresholds. Doctors group the earliest reliable signals as Core 1 biomarkers.
They include amyloid PET scans, spinal-fluid amyloid ratios, and accurate blood tests for p-tau217, which track amyloid or tau pathways before symptoms, according to the NIA-Alzheimer's Association review NIA-Alzheimer's Association review. Because of this biology, the 2024 criteria define Alzheimer's by biomarkers rather than memory scores alone. One abnormal Core 1 result can establish the diagnosis even when cognition tests normal.
Why do genes make the signal stronger?
The APOE4 gene variant raises the odds that early pathology is present. People with two copies face sharply faster risk, with over 95% of homozygotes over 65 showing Alzheimer's biomarkers and earlier symptom onset. Blood p-tau217 adds timing information.
In about 8,500 still-unimpaired people, high blood p-tau217 plus APOE4 predicted first symptoms roughly 3 to 6 years ahead, Columbia University Irving Medical Center reported for the Sept. 9 Lancet Neurology study Columbia University report. That combination does not diagnose dementia today. It flags a higher-risk group for closer follow-up and research.
Can you get tested without symptoms?
Usually no. The FDA-cleared tau PET tracer florquinitau F 18 makes tau tangles visible, but it is indicated only for cognitively impaired adults being evaluated, not for screening, according to the Pharmacy Times report on the FDA approval Pharmacy Times FDA approval report.
Guidelines still advise against testing people without symptoms outside research. Practical use now centers on selecting trial participants, clarifying an early workup, and planning ahead. For families considering research, useful steps include:.
- ask whether a prevention trial needs biomarker proof for entry
- bring new memory or thinking changes promptly for clinical workup
- use risk information for practical planning around work, support, and care wishes
What does a positive result mean?
A positive biomarker shows pathology or higher risk, not certainty. Many people with early changes never develop dementia on a predictable schedule. Test performance is also weakest at the earliest stage.
A negative tau scan does not exclude disease, and results need expert interpretation alongside age, health, and cognition. If you discuss testing, ask what test measures, who should not be tested, and how the result would change care or trial options. Do not pursue tau PET for reassurance screening.
